The number of corona virus infections in the country continues to fluctuate. On the other hand, it is expected to get the vaccination early next year. Meanwhile, All India Institute of Medical Sciences (AIIMS) director Dr Randeep Guleria says, ‘We now have vaccines in India which are in the final stages of testing. It is expected that by the end of this month or early next month we will get approval from the Indian regulatory authorities for the emergency use of the vaccine.
The AIIMS director also requested people to behave appropriately in view of Covid-19. He said that the emergency approval of the vaccine would start the vaccination program for the public. For this, work is going on at the central and state level in the war level in terms of building cold chains, providing suitable store warehouses, developing strategies, vaccination and availability of syringes.
AIIMS director said, ‘There is good data available here that vaccines are very safe. The safety and efficacy of the vaccine have not been compromised at all. 70 to 80 thousand volunteers have been vaccinated. No serious adverse effects were observed in them. Data suggests vaccine is safe in the short term. ‘
On the news of the vaccine’s impact during the Chennai trial, Dr. Guleria said, “The Chennai test case is more of an accidental incident than a vaccine.” When we vaccinate a large number of people, some of them may have some disease, which is not related to the vaccine. ‘
Regarding vaccination, AIIMS director said, ‘Initially the vaccine will not be available in sufficient quantity to be given to everyone. We need a priority list to see if we vaccinate people who are more likely to die due to Kovid. The elderly, suffering from other diseases and front line workers should be vaccinated first. After the booster dose is given, the vaccine will start producing a good amount of antibodies to the body.